Insulin-like growth factor-1 inversely correlated with liver fibrosis in diabetics
In type 2 diabetes mellitus (T2DM) patients without obvious alcohol consumption, levels of insulin-like growth factor-I (IGF-I) are inversely associated with liver fibrosis markers, a new study has found.
Using fasting blood samples collected from 415 T2DM patients (mean age 61.9±12.6 years; 248 males), researchers measured levels of IGF-I, as well as of other biomarkers such as fasting plasma glucose, glycated haemoglobin, and low- and high-density lipoprotein cholesterol.
Multiple linear regression analysis showed that IGF-I (B, –0.006; 95 percent CI, –0.009 to –0.004; p<0.0001) and its standard deviation (B, –0.17; –0.25 to –0.10; p<0.0001) were both significantly inversely associated with liver fibrosis, as measured by the fibrosis-4 (FIB-4) index.
A similar trend was observed between the 7S domain of type IV collagen (IV–7S), another measure of liver fibrosis, and IGF-I (B, –0.007; –0.01 to –0.003; p=0.0004) and its standard deviation (B, –0.23; –0.34 to –0.13; p<0.0001).
A subsequent longitudinal observational analysis divided patients into high and low IGF-I groups, using 96.0 ng/mL as the cutoff value. Researchers found that among those with low IGF-I, FIB-4 index scores over 3 years significantly worsened than among those in the high IGF-I group (p=0.049).
“[O]ur findings showed that low serum IGF-I levels are a possible risk factor for liver fibrosis in T2DM patients. This result might help clinicians to identify T2DM patients with advanced [nonalcoholic steatohepatitis] by measuring serum IGF-I levels. Therefore, we might need to pay attention to IGF-I in T2DM patients,” said researchers.